Combination therapy in multiple sclerosis

被引：14

作者：

Tullman M.J. ^{[1
]}

Lublin F.D. ^{[1
]}

机构：

[1] The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY 10029

来源：

Current Neurology and Neuroscience Reports | 2005年 / 5卷 / 3期

关键词：

Multiple Sclerosis; Multiple Sclerosis Patient; Expand Disability Status Scale; Progressive Multifocal Leukoencephalopathy; Natalizumab;

D O I：

10.1007/s11910-005-0053-9

中图分类号：

学科分类号：

摘要：

Over the past decade, multiple sclerosis (MS) has become a treatable neurologic illness. However, given the rather modest benefit of the currently available disease-modifying agents, as well as the challenges associated with performing placebo-controlled, equivalence, and superiority trials, the logic of combining therapies in MS has considerable appeal. Selecting agents for combination requires careful consideration, as the immunomodulating activity of one drug could potentially interfere with the therapeutic effect of another, and certain combinations may be associated with unforeseen adverse effects. Rigorously controlled studies are needed to determine the safest and most effective use of new and existing MS therapies. Copyright © 2005 by Current Science Inc.

引用

页码：245 / 248

页数：3

共 33 条

[1]

Jacobs L.D., Cookfair D.L., Rudick R.A., Et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Ann. Neurol., 39, pp. 285-294, (1996)

[2]

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, pp. 655-661, (1993)

[3]

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis, Lancet, 352, pp. 1498-1504, (1998)

[4]

Johnson K.P., Brooks B.R., Cohen J.A., Et al., Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: Rsults of a phase III multicenter, double-blind placebo-controlled trial, Neurology, 45, pp. 1268-1276, (1995)

[5]

Hartung H.P., Gonsette R., Konig N., Et al., Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial, Lancet, 360, pp. 2018-2025, (2002)

[6]

Lublin F.D., Baier M., Cutter G., Effect of relapses on development of residual deficit in multiple sclerosis, Neurology, 61, pp. 1528-1532, (2003)

[7]

Gomberg-Maitland M., Frison L., Halperin J.L., Active-control clinical trials to establish equivalence or noninferiority: Methodological and statistical concepts linked to quality, Am. Heart J., 146, pp. 398-403, (2003)

[8]

Edwards J.C., Szczepanski L., Szechinski J., Et al., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N. Engl. J. Med., 350, pp. 2572-2581, (2004)

[9]

Palella Jr. F.J., Delaney K.M., Moorman A.C., Et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N. Engl. J. Med., 338, pp. 853-860, (1998)

[10]

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis, Lancet, 337, pp. 441-446, (1991)

← 1 2 3 4 →